Survey of investigators' opinions on the acceptability of interactions with patients participating in clinical trials

Journal of Clinical Psychopharmacology

Volumn 30, Issue 3, 2010, Pages 323-327

  Dunlop, Boadie W ^a   Vaughan, Christopher L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Clinical trial; Ethics; Major depressive disorder; Placebo

Indexed keywords

PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH; HUMAN; MAJOR DEPRESSION; MALE; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

CLINICAL TRIALS, PHASE III AS TOPIC; DATA COLLECTION; DEPRESSIVE DISORDER, MAJOR; HUMANS; MULTICENTER STUDIES AS TOPIC; PHYSICIAN-PATIENT RELATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH PERSONNEL; TIME FACTORS;

EID: 77952412710     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181dc6b3e     Document Type: Article

References (18)

1. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLOS Med. 2008;5:260-268.
2. Turner E, Matthews A, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Eng J Med. 2008;358:252-260.
3. Walsh B, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287:1840-1847.
4. Sysko R, Walsh BT. A systematic review of placebo response in studies of bipolar mania. J Clin Psychiatry. 2007;68: 1213-1217.
5. Dunlop BW, Banja J. A renewed, ethical defense of placebo-controlled trials of new treatments for major depression and anxiety disorders. J Med Ethics. 2009;35:384-389.
6. Kobak KA, Kane JM, Thase ME, et al. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol. 2007;27:1-5.
7. Kobak KA, Feiger AD, Lipsitz JD. Interview quality and signal detection in clinical trials. Am J Psychiatry. 2005;162:628.
8. Rickels K. Non-Specific Factors in Drug Therapy. Springfield, IL: Charles C. Thomas; 1968.
9. Uhlenhuth EH, Rickels K, Fisher S, et al. Drug, doctor's verbal attitude and clinic setting in the symptomatic response to pharmacotherapy. Psychopharmacologia. 1966;9:392-418.
10. Schweizer E, Rickels K. Placebo response in generalized anxiety: its effect on the outcome of clinical trials. J Clin Psychiatry. 1997;58(suppl 11):30-38.
11. Fawcett J, Epstein P, Fiester SJ, et al. Clinical managementVimipramine/ placebo administration manual: NIMH Treatment of Depression Collaborative Research Program. Psychopharm Bull. 1987;23:309-324.
12. McKay KM, Imel ZE, Wampold BE. Psychiatrist effects in the psychopharmacological treatment of depression. J Aff Disord. 2006;92:287-290.
13. Krupnik JL, Sotsky SM, Simmens S, et al. The role of the therapeutic alliance in psychotherapy and pharmacotherapy outcome: findings in the National Institute of Mental Health treatment of depression collaborative research program. J Consult Clin Psychol. 1996;64: 532-539.
14. Blatt SJ, Zuroff DC. Empirical evaluation of the assumptions in identifying evidence based treatments in mental health. Clin Psychol Rev. 2005;25:459-486.
15. Butler AC, Chapman JE, Forman EM, et al. The empirical status of cognitive behavioral therapy: a review of meta-analyses. Clin Psychol Rev. 2006;26:17-31.
16. Linden M, Dierkes W, Munz T. Non-pharmacological treatment of psychiatrists in addition to the prescribing of an antidepressant drug. Eur Psychiatry. 2007;22:419-426.
17. Zimbroff DL. Patient and rater education of expectations in clinical trials (PREECT). J Clin Psychopharmacol. 2001;21:251-252.
18. Dunlop BW, Self RL. Exercise for depression: efficacy, safety and clinical trial implications. Psychopharm Bull. 2008;42:5-20.